Streetbeat News

Analyst Ratings

RIVN

Rivian Automotive's stock is trading higher due to a proposed U.S. ban on Chinese-made vehicles, which could reduce competition for Rivian. The company also benefits from reduced borrowing costs following a federal interest rate cut. Analysts have mixed ratings on Rivian, with a 12-month price target averaging $17.47.

Portfolio Pulse from Erica Kollmann

September 23, 2024 | 5:52 pm

LOW

Melius Research has initiated coverage on Lowe's Companies with a Buy rating and set a price target of $290.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 5:52 pm

TSCO

Melius Research has initiated coverage on Tractor Supply (NASDAQ:TSCO) with a Buy rating and set a price target of $315.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 5:50 pm

HD

Melius Research has initiated coverage on Home Depot with a Buy rating and set a price target of $420.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 5:48 pm

SFM

Melius Research has initiated coverage on Sprouts Farmers Market (NASDAQ:SFM) with a Hold rating and set a price target of $105.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 5:45 pm

BBY

Melius Research has initiated coverage on Best Buy Co (NYSE:BBY) with a Hold rating and set a price target of $100.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 5:44 pm

FND

Melius Research has initiated coverage on Floor & Decor Holdings with a Sell rating and set a price target of $80.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 5:42 pm

HSCS

Ascendiant Capital has reiterated its Buy rating on Heart Test Laboratories (NASDAQ:HSCS) and maintained a price target of $15.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 5:41 pm

CASY

Melius Research has initiated coverage on Casey's General Stores with a Buy rating and set a price target of $435.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 5:40 pm

REGN

Wells Fargo analyst Mohit Bansal has reiterated an Overweight rating on Regeneron Pharmaceuticals, maintaining a price target of $1200.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 5:37 pm